3 reports of this reaction
4.3% of all CALCAREA PHOSPHORICA reports
#13 most reported adverse reaction
MOVEMENT DISORDER is the #13 most commonly reported adverse reaction for CALCAREA PHOSPHORICA, manufactured by ANI Pharmaceuticals, Inc.. There are 3 FDA adverse event reports linking CALCAREA PHOSPHORICA to MOVEMENT DISORDER. This represents approximately 4.3% of all 70 adverse event reports for this drug.
Patients taking CALCAREA PHOSPHORICA who experience movement disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOVEMENT DISORDER is moderately reported among CALCAREA PHOSPHORICA users, representing a notable but not dominant share of adverse events.
In addition to movement disorder, the following adverse reactions have been reported for CALCAREA PHOSPHORICA:
The following drugs have also been linked to movement disorder in FDA adverse event reports:
MOVEMENT DISORDER has been reported as an adverse event in 3 FDA reports for CALCAREA PHOSPHORICA. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOVEMENT DISORDER accounts for approximately 4.3% of all adverse event reports for CALCAREA PHOSPHORICA, making it a notable side effect.
If you experience movement disorder while taking CALCAREA PHOSPHORICA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.